Physician profile
Nitin Rohatgi
NPI 1235161621
$814,087.52
in general payments reported to CMS, 2019-2025
25 companies · $170K in 2025
The $170K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67K · 2020: $49K · 2021: $65K · 2022: $153K · 2023: $117K · 2024: $193K · 2025: $170K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $406K · Travel and Lodging: $50K · Consulting Fee: $15K · Food and Beverage: $9,104 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $405,525.50 |
| Travel and Lodging | $49,907.67 |
| Consulting Fee | $14,725.00 |
| Food and Beverage | $9,103.87 |
| Education | $124.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $287,571.74 | 2020-2025 | Enhertu, Datroway, Lynparza |
| Lilly USA, LLC | $160,670.98 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Gilead Sciences, INC. | $93,592.40 | 2021-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $66,877.09 | 2019-2025 | Opdivo |
| Daiichi Sankyo INC. | $58,507.85 | 2020-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $32,189.24 | 2024-2025 | Keytruda, Lynparza |
| Stemline Therapeutics INC. | $24,437.51 | 2023-2024 | Orserdu |
| Puma Biotechnology, INC. | $23,623.43 | 2019-2020 | |
| Astellas Pharma US INC | $19,378.79 | 2024-2025 | Padcev |
| Pfizer INC. | $15,762.84 | 2020-2025 | |
| Eisai INC. | $9,023.04 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $5,014.60 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $3,940.48 | 2019 | |
| Janssen Biotech, INC. | $3,646.22 | 2019-2025 | Erleada |
| Exelixis INC. | $3,450.00 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $3,010.00 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $1,637.50 | 2022-2025 | Erleada |
| Aveo Pharmaceuticals, INC. | $1,050.00 | 2021 | |
| Athenex Pharmaceutical Division, LLC | $325.00 | 2020 | |
| Cardinal Health 110 LLC | $100.00 | 2020 | |
| Comsort, INC | $100.00 | 2019 | |
| Glaxosmithkline, LLC. | $100.00 | 2021 | |
| Tempus Ai, INC | $64.41 | 2025 | Xt Cdx |
| Genentech, INC. | $14.40 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitin Rohatgi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.